This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2862-2864, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2862-2864.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans

M. A. Pfaller,1,* S. A. Messer,1 R. J. Hollis,1 and R. N. Jones2,dagger

Department of Pathology, University of Iowa College of Medicine, Iowa City,1 and The Jones Group/JMI Laboratories, North Liberty,2 Iowa

Received 11 June 2001/Returned for modification 27 June 2001/Accepted 13 July 2001

Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of Candida spp. (3,312 isolates) and C. neoformans (373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as the test medium. Posaconazole was very active against all Candida spp. (MIC at which 90% of the isolates were inhibited [MIC90], 0.5 µg/ml; 97% of MICs were <= 1 µg/ml) and C. neoformans (MIC90, 0.5 µg/ml; 100% of MICs were <= 1 µg/ml). Candida albicans was the most susceptible species of Candida (MIC90, 0.06 µg/ml), and Candida glabrata was the least susceptible (MIC90, 4 µg/ml). Posaconazole was more active than itraconazole and fluconazole against all Candida spp. and C. neoformans. These results provide further evidence for the spectrum and potency of posaconazole against a large and geographically diverse collection of clinically important fungal pathogens.

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

dagger Present address: 345 Beaver Kreek Centre, North Liberty, IA 52317.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2862-2864, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2862-2864.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H (2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy 42: 1429-1438 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Gutierrez, M. O., Buitrago, M. J., Rodriguez-Tudela, J. L. (2008). Reliability of the WIDERYST Susceptibility Testing System for Detection of In Vitro Antifungal Resistance in Yeasts. Antimicrob. Agents Chemother. 52: 1062-1065 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program. J. Clin. Microbiol. 46: 551-559 [Abstract] [Full Text]  
  • Lortholary, O., Dannaoui, E., Raoux, D., Hoinard, D., Datry, A., Paugam, A., Poirot, J.-L., Lacroix, C., Dromer, F., the YEASTS Group, (2007). In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 51: 3378-3380 [Abstract] [Full Text]  
  • Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B., Pedicone, L. (2007). Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrob. Agents Chemother. 51: 812-818 [Abstract] [Full Text]  
  • Sansone-Parsons, A., Krishna, G., Simon, J., Soni, P., Kantesaria, B., Herron, J., Stoltz, R. (2007). Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers. Antimicrob. Agents Chemother. 51: 495-502 [Abstract] [Full Text]  
  • Espinel-Ingroff, A. (2006). Comparison of Three Commercial Assays and a Modified Disk Diffusion Assay with Two Broth Microdilution Reference Assays for Testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with Posaconazole and Amphotericin B. J. Clin. Microbiol. 44: 3616-3622 [Abstract] [Full Text]  
  • Gubbins, P. O., Krishna, G., Sansone-Parsons, A., Penzak, S. R., Dong, L., Martinho, M., Anaissie, E. J. (2006). Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.. Antimicrob. Agents Chemother. 50: 1993-1999 [Abstract] [Full Text]  
  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Sims, C. R., Paetznick, V. L., Rodriguez, J. R., Chen, E., Ostrosky-Zeichner, L. (2006). Correlation between Microdilution, E-test, and Disk Diffusion Methods for Antifungal Susceptibility Testing of Posaconazole against Candida spp.. J. Clin. Microbiol. 44: 2105-2108 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., Rodriguez-Tudela, J. L. (2006). Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrob. Agents Chemother. 50: 917-921 [Abstract] [Full Text]  
  • Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Topelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., Corcoran, G., Raad, I. (2006). Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.. Antimicrob. Agents Chemother. 50: 658-666 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Messer, S. A., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2005). Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43: 5208-5213 [Abstract] [Full Text]  
  • Pitisuttithum, P., Negroni, R., Graybill, J. R., Bustamante, B., Pappas, P., Chapman, S., Hare, R. S., Hardalo, C. J. (2005). Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56: 745-755 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Courtney, R., Sansone, A., Smith, W., Marbury, T., Statkevich, P., Martinho, M., Laughlin, M., Swan, S. (2005). Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease. J Clin Pharmacol 45: 185-192 [Abstract] [Full Text]  
  • Simitsopoulou, M., Gil-Lamaignere, C., Avramidis, N., Maloukou, A., Lekkas, S., Havlova, E., Kourounaki, L., Loebenberg, D., Roilides, E. (2004). Antifungal Activities of Posaconazole and Granulocyte-Macrophage Colony-Stimulating Factor Ex Vivo and in Mice with Disseminated Infection Due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48: 3801-3805 [Abstract] [Full Text]  
  • Pfaller, M. A., Espinel-Ingroff, A., Jones, R. N. (2004). Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Plate for Antifungal Susceptibility Testing of the New Triazoles Voriconazole, Posaconazole, and Ravuconazole. J. Clin. Microbiol. 42: 4577-4580 [Abstract] [Full Text]  
  • Trilles, L., Fernandez-Torres, B., dos Santos Lazera, M., Wanke, B., Guarro, J. (2004). In Vitro Antifungal Susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42: 4815-4817 [Abstract] [Full Text]  
  • Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., Courtney, R. (2004). Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects. Antimicrob. Agents Chemother. 48: 3543-3551 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002. J. Clin. Microbiol. 42: 3142-3146 [Abstract] [Full Text]  
  • Chau, A. S., Mendrick, C. A., Sabatelli, F. J., Loebenberg, D., McNicholas, P. M. (2004). Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles. Antimicrob. Agents Chemother. 48: 2124-2131 [Abstract] [Full Text]  
  • Courtney, R., Radwanski, E., Lim, J., Laughlin, M. (2004). Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men. Antimicrob. Agents Chemother. 48: 804-808 [Abstract] [Full Text]  
  • Xiao, L., Madison, V., Chau, A. S., Loebenberg, D., Palermo, R. E., McNicholas, P. M. (2004). Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14{alpha}-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding. Antimicrob. Agents Chemother. 48: 568-574 [Abstract] [Full Text]  
  • Li, X., Brown, N., Chau, A. S., Lopez-Ribot, J. L., Ruesga, M. T., Quindos, G., Mendrick, C. A., Hare, R. S., Loebenberg, D., DiDomenico, B., McNicholas, P. M. (2004). Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 53: 74-80 [Abstract] [Full Text]  
  • Dannaoui, E., Meis, J. F. G. M., Loebenberg, D., Verweij, P. E. (2003). Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrob. Agents Chemother. 47: 3647-3650 [Abstract] [Full Text]  
  • Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., Mangino, J. E., Lee, J. (2003). Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother. 47: 3149-3154 [Abstract] [Full Text]  
  • Tortorano, A. M., Rigoni, A. L., Biraghi, E., Prigitano, A., Viviani, M. A., the FIMUA-ECMM candidaemia study group, (2003). The European Confederation of Medical Mycology ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 52: 679-682 [Abstract] [Full Text]  
  • Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V. (2003). Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults. Antimicrob. Agents Chemother. 47: 2788-2795 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2002). Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility. J. Clin. Microbiol. 40: 3551-3557 [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Diekema, D. J. (2002). In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 46: 1723-1727 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J. (2002). Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole. J. Clin. Microbiol. 40: 1694-1697 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»